跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 364 条关于
“NX-3911”
全部
364
临床试验
132
药物
196
机构
1
资讯
35
上个月
Sanofi Initiates Phase 1 Trial of Oral STAT6 Degrader SAR448272, Triggering $10M Milestone Payment to Nurix
11个月前
Nurix Therapeutics Advances Bexobrutideg Toward Pivotal CLL Trials with Strong Phase 1 Data
2年前
FDA Grants Fast Track Designation to Nurix Therapeutics' NX-5948 for Relapsed/Refractory CLL/SLL
去年
Nurix Therapeutics Advances BTK Degrader NX-5948 and Reinitiates NX-2127 Trial
去年
Nurix Therapeutics' NX-5948 Receives FDA Fast Track for Waldenstrom's Macroglobulinemia
去年
NX Taiwan Achieves Historic Medical Device QMS Certification, First Among Japanese Companies
去年
NX-5948, a Novel BTK Degrader, Shows High Response Rates in Pretreated CLL/SLL
去年
Nurix Therapeutics' BTK Degrader NX-5948 Shows Promise in Waldenstrom's Macroglobulinemia
11个月前
Nurix Therapeutics' NX-1607 Shows 49.3% Disease Control Rate in First-in-Class CBL-B Inhibitor Trial
去年
Nurix Therapeutics' NX-5948 Receives EMA PRIME Designation for Relapsed/Refractory CLL
第 1 页,共 4 页
上一页
下一页